2008-07-02 15:59:17 -
www.companiesandmarkets.com adds new report - Premium Company Profile - Idenix Pharmaceuticals, Inc. www.companiesandmarkets.com/Summary-Company-Profile/Premium-Comp ..
Introduction
Idenix Pharmaceuticals develops drugs for the treatment of human viral and other infectious diseases. Novartis is the major shareholder of the company owning 56% of Idenix and has development and worldwide marketing rights for Idenix´s HBV and HCV franchise.
Scope
Contains corporate strategy, value chain presence and SWOT Analysis
Provides detailed business description, segment analysis, 5-year financial trends, key
products and key competitors
Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights
Idenix currently focuses on the development and commercialization of drugs for the treatment of hepatitis C and human immuno viral infections. The company´s only approved product, Tyzeka/Sebivo for the hepatitis B virus, is developed, manufactured and marketed by Novartis and Idenix receives royalties on the product sales
The company´s total revenues increased at a CAGR of 110% from $3 million to $67 million during 2002-2006, representing an absolute growth of +$64 million. As the company launched approved product Tyzeka in October 2006, it recorded $0.6 million of revenues from product sales in fiscal 2006
Idenix´s revenues are forecast to increase from $67 million in 2006 to $198 million in 2010, growing at a CAGR of 31%. This represents an absolute growth of +$131 million during the period. Collaboration and license revenues from Novartis are expected to be the largest contributor to the company´s overall revenue growth
Reasons to Purchase
Access all the important information and analysis on the company in a single report
Understand company´s strengths, weaknesses, opportunities and threats along with business strategy and value chain
Gain access to company´s adjusted five year financial data along with key ratios and market capitalization
